These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25694534)

  • 1. The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice.
    Suyama K; Kawasaki Y; Miyazaki K; Kanno S; Ono A; Ohara S; Sato M; Hosoya M
    Nephrol Dial Transplant; 2015 Jun; 30(6):969-77. PubMed ID: 25694534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of the N-Terminal Domain of Thrombomodulin and the Potential of Recombinant Human Thrombomodulin as a Therapeutic Intervention for Shiga Toxin-Induced Hemolytic-Uremic Syndrome.
    Kröller S; Schober J; Krieg N; Dennhardt S; Pirschel W; Kiehntopf M; Conway EM; Coldewey SM
    Toxins (Basel); 2024 Sep; 16(9):. PubMed ID: 39330867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diet-induced obesity precipitates kidney dysfunction and alters inflammatory mediators in mice treated with Shiga Toxin 2.
    Harrison LM; Gaines DW; Babu US; Balan KV; Reimschuessel R; Do AB; Pereira MR; Bigley EC; Ferguson M; Mehta A; Williams KM
    Microb Pathog; 2018 Oct; 123():250-258. PubMed ID: 30016681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.
    Zoja C; Locatelli M; Pagani C; Corna D; Zanchi C; Isermann B; Remuzzi G; Conway EM; Noris M
    J Immunol; 2012 Oct; 189(7):3661-8. PubMed ID: 22942429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of recombinant human soluble thrombomodulin for childhood hemolytic uremic syndrome.
    Kawasaki Y; Suyama K; Ono A; Oikawa T; Ohara S; Suzuki Y; Sakai N; Hosoya M
    Pediatr Int; 2013 Oct; 55(5):e139-42. PubMed ID: 24134770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
    Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
    J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Willebrand Factor expression in a Shiga toxin-mediated primate model of hemolytic uremic syndrome.
    Pysher TJ; Siegler RL; Tesh VL; Taylor FB
    Pediatr Dev Pathol; 2002; 5(5):472-9. PubMed ID: 12196894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin.
    Ikeda M; Ito S; Honda M
    Pediatr Nephrol; 2004 May; 19(5):485-9. PubMed ID: 15007712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality.
    Palermo M; Alves-Rosa F; Rubel C; Fernández GC; Fernández-Alonso G; Alberto F; Rivas M; Isturiz M
    Clin Exp Immunol; 2000 Jan; 119(1):77-83. PubMed ID: 10606967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse model for hemolytic uremic syndrome induced by outer membrane vesicles of Escherichia coli O157:H7.
    Kim SH; Lee YH; Lee SH; Lee SR; Huh JW; Kim SU; Chang KT
    FEMS Immunol Med Microbiol; 2011 Dec; 63(3):427-34. PubMed ID: 22029600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of vascular endothelial growth factor and angiopoietin 1 in renal injury in hemolytic uremic syndrome.
    Ohara S; Kawasaki Y; Abe Y; Watanabe M; Ono A; Suyama K; Hashimoto K; Honda T; Suzuki J; Hosoya M
    Am J Nephrol; 2012; 36(6):516-23. PubMed ID: 23171542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of interleukin-10 reduces progression of shiga toxin-induced hemolytic uremic syndrome.
    Pineda GE; Rearte B; Todero MF; Bruballa AC; Bernal AM; Fernandez-Brando RJ; Isturiz MA; Zotta E; Alba-Soto CD; Palermo MS; Ramos MV
    Clin Sci (Lond); 2021 Feb; 135(3):575-588. PubMed ID: 33496327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.
    Locatelli M; Buelli S; Pezzotta A; Corna D; Perico L; Tomasoni S; Rottoli D; Rizzo P; Conti D; Thurman JM; Remuzzi G; Zoja C; Morigi M
    J Am Soc Nephrol; 2014 Aug; 25(8):1786-98. PubMed ID: 24578132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profile and injury sites in mice treated with Shiga toxin 2 and lipopolysaccharide as a Shiga toxin-associated hemolytic uremic syndrome model.
    Kume Y; Go H; Maeda R; Suyama K; Mori T; Kawasaki Y; Hashimoto K; Hosoya M
    Physiol Genomics; 2022 May; 54(5):153-165. PubMed ID: 35384732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model.
    Palermo MS; Alves Rosa MF; Van Rooijen N; Isturiz MA
    Clin Exp Immunol; 1999 Jun; 116(3):462-7. PubMed ID: 10361235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of p38 MAP kinase pathway in a toxin-induced model of hemolytic uremic syndrome.
    Fu XJ; Iijima K; Nozu K; Hamahira K; Tanaka R; Oda T; Yoshikawa N; Matsuo M
    Pediatr Nephrol; 2004 Aug; 19(8):844-52. PubMed ID: 15206036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LPS-primed CD11b
    Niu S; Paluszynski J; Bian Z; Shi L; Kidder K; Liu Y
    Sci Rep; 2018 Mar; 8(1):3994. PubMed ID: 29507316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease.
    Keepers TR; Psotka MA; Gross LK; Obrig TG
    J Am Soc Nephrol; 2006 Dec; 17(12):3404-14. PubMed ID: 17082244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease of thrombomodulin contributes to the procoagulant state of endothelium in hemolytic uremic syndrome.
    Fernández GC; Te Loo MW; van der Velden TJ; van der Heuvel LP; Palermo MS; Monnens LL
    Pediatr Nephrol; 2003 Oct; 18(10):1066-8. PubMed ID: 12920633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal prostacyclin biosynthesis in a baboon model of Shiga toxin mediated hemolytic uremic syndrome.
    Siegler RL; Pysher TJ; Tesh VL; Taylor FB
    Nephron; 2002 Oct; 92(2):363-8. PubMed ID: 12218315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.